Commonwealth Numbered Regulations

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) AMENDMENT REGULATIONS 2010 (NO.5) (SLI NO 296 OF 2010)

TABLE OF PROVISIONS

   PART 1--PRELIMINARY

   1.      Name of Regulations  
   2.      Commencement  
   3.      Amendment of National Health (Pharmaceutical Benefits) Regulations 1960  

   PART 2--TRANSITIONAL

   4.      Definitions for Part 2  
   5.      Transitional -- listed brand subject to price disclosure and annual reporting period ends before 1 December 2010  
   6.      Transitional -- listed brand subject to price disclosure and annual reporting period does not end before 1 December 2010 -- data collection period  
   7.      Transitional -- listed brand subject to price disclosure and annual reporting period does not end before 1 December 2010 -- reporting period and information  
   8.      Transitional -- listed brand having same drug and manner of administration as listed brand already subject to price disclosure requirements -- first reporting period for brand in third transitional cycle  
   9.      Transitional -- listed brand moving from first or second transitional disclosure cycle to main disclosure cycle  
   10.     Transitional -- listed brand moving from third transitional disclosure cycle to main disclosure cycle  
           SCHEDULE 1 Amendments